Your browser doesn't support javascript.
loading
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala, Simona; Codilupi, Tamara; Brkic, Sime; Baerenwaldt, Anne; Ghosh, Nilabh; Hao-Shen, Hui; Dirnhofer, Stephan; Dettmer, Matthias S; Simillion, Cedric; Kaufmann, Beat A; Chiu, Sophia; Keller, Matthew; Kleppe, Maria; Hilpert, Morgane; Buser, Andreas S; Passweg, Jakob R; Radimerski, Thomas; Skoda, Radek C; Levine, Ross L; Meyer, Sara C.
Afiliación
  • Stivala S; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Codilupi T; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Brkic S; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Baerenwaldt A; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Ghosh N; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Hao-Shen H; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Dirnhofer S; Department of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
  • Dettmer MS; Department of Pathology and.
  • Simillion C; Department of BioMedical Research, University of Berne, Berne, Switzerland.
  • Kaufmann BA; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Chiu S; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Keller M; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Kleppe M; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Hilpert M; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Buser AS; Division of Hematology, University Hospital Basel, Basel, Switzerland.
  • Passweg JR; Division of Hematology, University Hospital Basel, Basel, Switzerland.
  • Radimerski T; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Skoda RC; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Levine RL; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Meyer SC; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
J Clin Invest ; 129(4): 1596-1611, 2019 03 04.
Article en En | MEDLINE | ID: mdl-30730307
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Hematológicas / Mutación Missense / Sistema de Señalización de MAP Quinasas / Inhibidores de Proteínas Quinasas / Janus Quinasa 2 / Trastornos Mieloproliferativos / Proteínas de Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Clin Invest Año: 2019 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Hematológicas / Mutación Missense / Sistema de Señalización de MAP Quinasas / Inhibidores de Proteínas Quinasas / Janus Quinasa 2 / Trastornos Mieloproliferativos / Proteínas de Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Clin Invest Año: 2019 Tipo del documento: Article País de afiliación: Suiza